In vivo liposomal delivery of PPARα/γ dual agonist tesaglitazar in a model of obesity enriches macrophage targeting and limits liver and kidney drug effects.
Osinski V, Bauknight DK, Dasa SSK, Harms MJ, Kroon T, Marshall MA, Garmey JC, Nguyen AT, Hartman J, Upadhye A, Srikakulapu P, Zhou A, O'Mahony G, Klibanov AL, Kelly KA, Boucher J, McNamara CA.
Osinski V, et al. Among authors: klibanov al.
Theranostics. 2020 Jan 1;10(2):585-601. doi: 10.7150/thno.36572. eCollection 2020.
Theranostics. 2020.
PMID: 31903139
Free PMC article.